Loading clinical trials...
Loading clinical trials...
An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis
Conditions
Interventions
bevacizumab [Avastin]
carboplatin
+2 more
Locations
25
France
Bordeaux, France
Brest, France
Caen, France
Chartres, France
Créteil, France
Gap, France
Start Date
April 1, 2009
Primary Completion Date
October 1, 2012
Completion Date
October 1, 2012
Last Updated
November 19, 2014
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions